Home
Celcuity

Celcuity Market Share Analysis for August 2026

Targeted therapies only work when inhibiting the target pathway disrupts the oncogenic process. Celcuity’s platform provides unparalleled insights into oncogenic pathways. We harness these insights to develop new targeted therapies for cancer patients. Our lead candidate is gedatolisib, a pan-PI3K, mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (PAM) pathway.

Industry: N/A

Domaincelcuity.com

Year Founded2012

Employees51 - 200

Annual Revenue$15M - $25M

Celcuity

Celcuity (including company regionals)

celcuity.com

See more website traffic and engagement information

Celcuity Revenue up to August 2026 is 15M - 25M

revenue generated by Celcuity top domains

Celcuity top domains revenue over 3 years

Revenue for Celcuity top domains

celcuity.com15M - 25M

See more with Sales Intelligence

Total visits to Celcuity's top domains

Understand Celcuity market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

celcuity.com8.1K

See more with Sales Intelligence

Avg. visit duration in Celcuity's top domains

Analyze Celcuity engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

celcuity.com00:00:19

See more with Sales Intelligence

Avg. pageviews on Celcuity's top domains

See how Celcuity keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

celcuity.com1.72

See more with Sales Intelligence

Celcuity top competitors by domain

Top similar sites in August 2026, ranked by their affinity

onclive.comCompany NameOncLiveEmployees51 - 200HQUnited States, New Jersey, CranburyAnnual revenue$5M - $10MTotal visits247.8KHealth > Health Conditions and Concerns

Top technologies used by Celcuity

These are the website technologies, by industry, used by Celcuity top domains

eCommerce (4)

WooCommerce

Widget (4)

Twemoji

Advertising (2)

DoubleClick

Conversion & Analytics (2)

Google Analytics

More Technologies

10

See all

News & Signals from Celcuity

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsCelcuity Inc. had revenue of $90K on Aug 14th '26.* Celcuity shares fell 6.0% to open at $86.60 after the company reported a quarterly EPS loss of $1.44, missing estimates, while revenue of $0.09 million came in well below the $4.42 million consensus.

NewsCelcuity Inc. launched Revtorpyk gedatolisib on Aug 1st '26.Celcuity Inc. (NASDAQ:CELC) plans to launch Revtorpyk gedatolisib this quarter; it licensed the mTOR and PI3K inhibitor from Pfizer Inc. (NYSE:PFE) in 2021.

NewsKazia Therapeutics Limited identified as competitor of Celcuity, LLC..This afternoon, one of KZIA's competitors, CELC, reported that the FDA has approved Revtorpyk (gedatolisib) in combination with fulvestrant, with or without palbociclib, for treating HR+/HER2- locally advanced or metastatic breast cancer without PIK3CA mutation following progression on or after treatment with at least one line of endocrine therapy.